目的：观察平艾合剂I号方治疗艾滋病的疗效。方法：将107 例患者分为单服平艾合剂I号方（太芪培元颗粒）组与平艾合剂I号方合用西药（齐多夫定300 mg、拉米夫定150 mg、奈韦拉平200 mg，每日两次）组，即中医组与中西医组。结果：经6 个月治疗后，中医组患者中医证候积分、卡洛夫斯基积分、CD4+ T 淋巴细胞计数改善程度较中西医组明显，且差异有统计学意义。结论：平艾合剂I号方有改善艾滋病患者症状，提高免疫力和生存质量的作用。

This study was aimed to observe the clinical effect of Ping-Ai Granules I in the treatment of HIV/AIDS. A total of 107 AIDS cases were divided into Ping-Ai Granules I group and Ping-Ai Granules I united with HAART group. The results showed that there was significant difference between Ping-Ai Granules I group and Ping-Ai Granules I united with HAART group in aspects of symptoms, physical signs, Karnovsky Score and changes of CD4+ T lymphocyte. It was concluded that Ping-Ai Granules I had the function of improving patient's symptom and increasing patient's immunity and living quality.

新疆维吾尔自治区科技厅科研机构创新发展专项（2013008）：新疆艾滋病防治体系内中医药推广应用与研究，负责人：马建萍；科学技术部国家“十二五”重大科技专项（2012ZX10005010-001）：中医药防治重大传染病临床科研基地与技术平台建设———中医药防治艾滋病临床科研基地建设，总课题负责人：张永利，子课题负责人：李兴旺。